Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current status and recent developments in anthracenone antipsoriatics.

K Müller1

  • 1Institut für Pharmazeutische Chemie, Westfälische Wilhelms-Universität Münster, Hittorfstrasse 58-62, Münster, D-48149, Germany. kmuller@uni-muenster.de

Current Pharmaceutical Design
|June 1, 2000
PubMed
Summary

Anthralin, a potent psoriasis treatment, causes inflammation due to oxygen radical production. Modifying its structure can reduce side effects while maintaining efficacy for improved topical psoriasis therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lichen metabolites. 1. Inhibitory action against leukotriene B4 biosynthesis by a non-redox mechanism.

Journal of natural products·1999
Same author

Reconstitution of the actin-scavenger system after orthotopic liver transplantation for end-stage liver disease: a prospective and longitudinal study.

Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·1999
Same author

Inhibition of keratinocyte growth by different Nepalese zanthoxylum species.

Phytotherapy research : PTR·1999
Same author

Early gene expression of NK cell-activating chemokines in mice resistant to Leishmania major.

Infection and immunity·1999
Same author

A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo.

Bone·1999
Same author

Overexpression of a C-terminal fragment of presenilin 1 delays anti-Fas induced apoptosis in Jurkat cells.

Neuroscience letters·1999

Area of Science:

  • Dermatology
  • Pharmacology
  • Biochemistry

Background:

  • Psoriasis treatment is evolving with new topical agents.
  • Anthralin (anthracenone antipsoriatic) effectively clears psoriasis but causes skin inflammation and staining.
  • Its mechanism involves redox chemistry and oxygen radical generation, impacting macromolecules.

Purpose of the Study:

  • To review strategies for minimizing anthralin-induced skin inflammation.
  • To explore controlling oxygen radical generation for novel anthracenone design.
  • To evaluate structural modifications of anthralin for improved psoriasis therapy.

Main Methods:

  • Focus on current strategies to mitigate anthralin's inflammatory potential.
  • Investigate controlling and manipulating oxygen radical generation.

Related Experiment Videos

  • Analyze in vitro studies altering anthralin structure to modulate enzyme inhibition and radical production.

    • Main Results:

    • Altering anthralin's structure can significantly change its in vitro profile.
    • Modified anthralin derivatives show potent 5-lipoxygenase inhibition, retaining antiproliferative activity.
    • Structural changes lead to diminished oxygen radical generation and reduced proinflammatory action.

    Conclusions:

    • Structural modification of anthralin is key to reducing inflammation and side effects.
    • Derivatives with phenylacyl substituents at the 10-position show promise for improved topical psoriasis treatment.
    • Rational design of novel anthracenones can enhance psoriasis therapy by controlling radical generation.